Cargando…

Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes

BACKGROUND: Calcimimetic treatment of secondary hyperparathyroidism in chronic dialysis patients is often followed by hypocalcemia. METHODS: We investigated the frequency, predictors, consequences and therapeutic responses following cinacalcet-induced hypocalcemia in an incident European hemodialysi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Louie, Karly S., Erhard, Clement, Wheeler, David C., Stenvinkel, Peter, Fouqueray, Bruno, Floege, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381480/ https://www.ncbi.nlm.nih.gov/pubmed/31848883 http://dx.doi.org/10.1007/s40620-019-00686-z

Ejemplares similares

Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries
por: Fuller, Douglas S., et al.
Publicado: (2019)

Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population
por: Floege, Jürgen, et al.
Publicado: (2011)

Cinacalcet in HIV haemodialysis patients
por: Belmouaz, Simohamed, et al.
Publicado: (2008)

SAT-355 Severe Symptomatic Hypocalcemia Related to Cinacalcet Administration Introduction
por: Weaver, Travis, et al.
Publicado: (2020)

Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?
por: Rottembourg, Jacques, et al.
Publicado: (2018)

Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study
por: Fotheringham, James, et al.
Publicado: (2020)

Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study
por: Fotheringham, James, et al.
Publicado: (2020)

Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial
por: Wheeler, David C., et al.
Publicado: (2014)

Severe Symptomatic Hypocalcemia, complicating cardiac arrhythmia following Cinacalcet (Sensipar(TM)) administration: A Case Report
por: Schmidt, Gregory S., et al.
Publicado: (2021)

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet
por: Chen, Ping, et al.
Publicado: (2019)

Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all‐cause mortality
por: Gillespie, Iain A., et al.
Publicado: (2015)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate: when should cinacalcet hydrochloride be administered?
por: Date, Toshiyuki, et al.
Publicado: (2008)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

A haemodialysis patient with back pain: brown tumour as a cause of spinal cord compression under cinacalcet therapy
por: Kampschreur, Linda M., et al.
Publicado: (2010)

Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial
por: Liu, Lin, et al.
Publicado: (2020)

A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
por: Eddington, Helen, et al.
Publicado: (2021)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Hypocalcemia as a predictor of mortality and transfusion. A scoping review of hypocalcemia in trauma and hemostatic resuscitation
por: Kronstedt, Shane, et al.
Publicado: (2022)

Cinacalcet: the chemical parathyroidectomy?
por: Bellasi, Antonio, et al.
Publicado: (2013)

Cinacalcet: A Viable Therapeutic Option for Primary Hyperparathyroidism in the Elderly
por: Abusahmin, Hussam, et al.
Publicado: (2018)

Marked increase in bone formation markers after cinacalcet treatment by mechanisms distinct from hungry bone syndrome in a haemodialysis patient
por: Goto, Shunsuke, et al.
Publicado: (2010)

Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study
por: Rottembourg, Jacques, et al.
Publicado: (2019)

A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients
por: Nilsson, Erik, et al.
Publicado: (2016)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Hypercalcemia of malignancy treated with cinacalcet
por: Asonitis, Nikolaos, et al.
Publicado: (2017)

PTH Gradient as a Predictor of Post Thyroidectomy Hypocalcemia
por: Garg, Surabhi, et al.
Publicado: (2021)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

PTH after Thyroidectomy as a Predictor of Post-Operative Hypocalcemia
por: Metere, Alessio, et al.
Publicado: (2021)

Utility of Cinacalcet in Familial Hypocalciuric Hypercalcemia
por: Sethi, Bipin Kumar, et al.
Publicado: (2017)

Predictors of Hypocalcemia after Thyroidectomy: Results from the Nationwide Inpatient Sample
por: Baldassarre, Randall L., et al.
Publicado: (2012)

Predictors of early postoperative hypocalcemia after total parathyroidectomy in renal hyperparathyroidism
por: Tan, Poh Guan, et al.
Publicado: (2020)

Adjusted calcium concentration as a predictor of ionized hypocalcemia in hypoalbuminemic dogs
por: De Witte, Fiamma, et al.
Publicado: (2021)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality
por: Samal, S. K., et al.
Publicado: (2020)

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)

A novel asymmetric synthesis of cinacalcet hydrochloride
por: Arava, Veera R, et al.
Publicado: (2012)

The effects of discontinuing cinacalcet at the time of kidney transplantation
por: Jadoul, Michel, et al.
Publicado: (2010)

Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications
por: di Filippo, Luigi, et al.
Publicado: (2021)

Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients
por: Kim, Jwa-Kyung, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mhpc3kmg9l4sfu7hq4n5bqocr9